From the Journals

Adverse event reporting in second-dose varicella vaccination shows no surprises


 

No new or unexpected adverse events were reported in association with second-dose varicella vaccination in children age 4-18 years during 2006-2014.

During the study period of 2006-2014, 14,641 reports regarding second-dose varicella vaccinations were made to the Vaccine Adverse Event Reporting System, according to John Su, MD, PhD, and his associates. Of these reports, only 3% were serious adverse events (AE), with the most common nonserious AE being injection-site reaction, which occurred in 48% of patients age 4-6 years reporting AEs, and in 38% of patients age 7-18 years reporting AEs.

Of the 494 serious AEs reported, pyrexia was the most common in children age 4-6 years, and headache and vomiting were the most common in children age 7-18 years. A total of seven deaths from various causes were reported, though no causal relation to vaccination was seen, and significant chronic medical problems were common in these children.

“The safety data on second-dose varicella vaccination are reassuring,” the investigators noted. “Reported AEs after second-dose varicella vaccination were mild, self limiting, and similar in reported frequency to AEs after first-dose vaccination, with no new or unexpected safety concerns.”

Find the full study in Pediatrics (2017 Feb 7. doi: 1542/peds.2016-2536).

Recommended Reading

Statin use increases risk of herpes zoster
MDedge Infectious Disease
PCV effective against HNIs, pHNIs that require hospitalization in immunized children
MDedge Infectious Disease
Children in United States vaccinated for polio elsewhere may require revaccination
MDedge Infectious Disease
Double-dose influenza vaccine effective against type B strains
MDedge Infectious Disease
Childhood PCV program produces overall protection
MDedge Infectious Disease
Don’t delay pneumococcal conjugate vaccine for preterm infants
MDedge Infectious Disease
It isn’t over until it’s over
MDedge Infectious Disease
Teen vaccines: Where we are now, and how can we go further?
MDedge Infectious Disease
Model: Quadrivalent vaccine could cost effectively cut MSM’s HPV-related cancers
MDedge Infectious Disease
ACIP releases updated guidance for adult vaccinations
MDedge Infectious Disease